Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Prostate Cancer treatment details. Immunotherapy. Seattle Cancer Care Alliance, Seattle, WA, United States

Survival: 35.0 months
Toxicity Grade: 5
Treatments: Immunotherapy
Country: United States
City/State/Province: Seattle, WA
Hospital: Seattle Cancer Care Alliance
Journal: Link
Date: 9/2008

Patients: This phase I/II study involved 80 men with metastatic, hormone refractory prostate cancer. Their median age was 69, ranging from 49 to 90 years old.

Treatment: Patients were treated with one of three different doses (amounts) of an immunotherapy, developed from prostate cancer cell lines that were modified with a stimulating molecule, GM-CSF.

Toxicity: All patients experienced a reaction at the injection site, including erythema, induration, pruritis, and pain or soreness. Nausea, anorexia, anemia, thrombocytopenia, dyspnea, fatigue, peripheral edema, and weight loss were reported, each in less than 10% of patients. Grade 3 and 4 toxicities were reported in four patients; fatigue, deep vein thrombosis, thrombocytopenia, anemia, hematoma, and weight loss. Four patients died while on this study, two from disease progression, one from chronic obstructive lung disease, and one from an unknown cause.

Results: The median overall survival was 35 months for patients treated with the highest dose, 23.1 months for the low-dose group, and 20 months for the middle-dose group.

Support: This study was supported by Cell Genesys, which developed the therapy used in this study.

Correspondence: Dr. Celestia S. Higano

E-mail to a Friend Email Physician More Information